{"DataElement":{"publicId":"3844251","version":"1","preferredName":"Other Leukemia Status Chronic Lymphocytic Leukemia Prolymphocytic Leukemia Hairy Cell Leukemia Type","preferredDefinition":"A description of chronic lymphocytic leukemia, prolymphocytic leukemia, hairy cell leukemia for other leukemia.","longName":"3844232v1.0:2688886v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3844232","version":"1","preferredName":"Other Leukemia Status","preferredDefinition":"Different than the one(s) previously specified or mentioned._A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years._A condition or state at a particular time.","longName":"2685376v1.0:2320064v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2685376","version":"1","preferredName":"Other Leukemia","preferredDefinition":"Not otherwise specified.:A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","longName":"C17649:C3161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAD6C97-F7CC-1A52-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320064","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037B-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E37048E2-01BB-C58E-E040-BB89AD4363B7","latestVersionIndicator":"Yes","beginDate":"2013-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-08-08","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3946592","version":"1","preferredName":"Chronic Lymphocytic Leukemia Prolymphocytic Leukemia Hairy Cell Leukemia Status Type","preferredDefinition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)_A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen._A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001)_A condition or state at a particular time._Something distinguishable as an identifiable class based on common qualities.","longName":"3946592v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Untreated","valueDescription":"Never Therapeutic Procedure","ValueMeaning":{"publicId":"2685077","version":"1","preferredName":"Never Therapeutic Procedure","longName":"2685077","preferredDefinition":"Not ever; at no time in the past (or future).: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Never","conceptCode":"C70543","definition":"Not ever; at no time in the past (or future).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B83BB14-A509-653C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-02","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA872AD2-6E0B-CB3C-E040-BB89AD4313A5","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"SBR","dateModified":"2016-08-16","deletedIndicator":"No"},{"value":"Stable disease (SD)","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2560100","version":"1","preferredName":"Stable Disease","longName":"2560100","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA880C04-9273-5D97-E040-BB89AD430334","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"SBR","dateModified":"2016-08-16","deletedIndicator":"No"},{"value":"Nodular partial remission (nPR)","valueDescription":"Nodular Partial Remission","ValueMeaning":{"publicId":"2724515","version":"1","preferredName":"Nodular Partial Remission","longName":"2724515","preferredDefinition":"Remission with persistent lymphoid nodules in the bone marrow","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Partial Remission","conceptCode":"C70633","definition":"Remission with persistent lymphoid nodules in the bone marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4450D85F-4EF5-43BF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA872AD2-6E1F-CB3C-E040-BB89AD4313A5","beginDate":"2008-01-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"ONEDATA","dateModified":"2013-11-06","deletedIndicator":"No"},{"value":"Partial remission (PR)","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"2577916","version":"1","preferredName":"Partial Remission","longName":"2577916","preferredDefinition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD69-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA872AD2-6E29-CB3C-E040-BB89AD4313A5","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"ONEDATA","dateModified":"2013-11-06","deletedIndicator":"No"},{"value":"Progressive disease (Prog)","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"2559908","version":"1","preferredName":"Progressive Disease","longName":"2559908","preferredDefinition":"Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B711-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"HARTLEYG","dateModified":"2014-10-10","changeDescription":"Manually Curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA872AD2-6E33-CB3C-E040-BB89AD4313A5","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"SBR","dateModified":"2016-08-16","deletedIndicator":"No"},{"value":"Relapse (untreated)","valueDescription":"Without Therapeutic Procedure Recurrent Disease","ValueMeaning":{"publicId":"2688887","version":"1","preferredName":"Without Therapeutic Procedure Recurrent Disease","longName":"2688887","preferredDefinition":"Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: the return of a sign, symptom, or disease after a remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4ABC47-79F8-3D22-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA872AD2-6E3D-CB3C-E040-BB89AD4313A5","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"ONEDATA","dateModified":"2013-11-06","deletedIndicator":"No"},{"value":"Complete remission (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"2577915","version":"1","preferredName":"Complete Remission","longName":"2577915","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EA880C04-925F-5D97-E040-BB89AD430334","beginDate":"2007-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"ONEDATA","dateModified":"2013-11-06","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"Negation Assessment","ValueMeaning":{"publicId":"4982117","version":"1","preferredName":"Negation Assessment","longName":"4982117","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: The final result of a determination of the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E13FD74-CDF7-22DE-E050-BB89AD4352E6","latestVersionIndicator":"Yes","beginDate":"2015-08-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3CDDE1C8-E292-12F4-E053-F662850A3CBC","beginDate":"2016-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-09-19","modifiedBy":"ONEDATA","dateModified":"2016-09-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3946591","version":"1","preferredName":"Chronic Lymphocytic Leukemia Prolymphocytic Leukemia Hairy Cell Leukemia Status Type","preferredDefinition":"The most common type of chronic lymphoid leukemia. It comprises 90% of chronic lymphoid leukemias in the United States. Morphologically, the neoplastic cells are small, round B-lymphocytes. This type of leukemia is not considered to be curable with available therapy. (WHO, 2001):PLL. A type of chronic lymphocyctic leukemia (CLL), in which too many immature white blood cells (prolymphocytes) are found in the blood and bone marrow. PLL usually progresses more rapidly than classic CLL.:A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001):A condition or state at a particular time.:Something distinguishable as an identifiable class based on common qualities.","longName":"3946591v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Prolymphocytic Leukemia","conceptCode":"C3181","definition":"A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA872AD2-6DDA-CB3C-E040-BB89AD4313A5","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"ONEDATA","dateModified":"2013-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA872AD2-6DEB-CB3C-E040-BB89AD4313A5","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"KUMMEROA","dateModified":"2016-09-19","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PreTed_prime_dis_hct_oth_lk_cll_pll_hcl_stat","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What is the other leukemia st","type":"Preferred Question Text","description":"What is the other leukemia status chronic lymphocytic leukemia,  prolymphocytic leukemia, hairy cell leukemia type?","url":null,"context":"NHLBI"},{"name":"What was the disease status?","type":"Alternate Question Text","description":"What was the disease status?","url":null,"context":"NHLBI"},{"name":"What was the disease status?","type":"Application Standard Question Text","description":"What was the disease status?","url":null,"context":"NHLBI"},{"name":"BRIDG Mapping for CDE:3844251","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis.value = {other leukemia} AND PerformedDiagnosis > PerformedObservation.dateRange IS LESS THAN OR EQUAL TO PerformedSubstanceAdministration.dateRange AND PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Administer Hematopoietic Cell Product {Transplantation}\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E37048E2-01CE-C58E-E040-BB89AD4363B7","latestVersionIndicator":"Yes","beginDate":"2013-08-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-08-08","modifiedBy":"ALEYR","dateModified":"2019-04-13","changeDescription":".1/15/14mn-added BRIDG info. Added human readable def. System generated def displayed as alt def. No version needed. AK 11/18/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}